These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20218017)

  • 1. HIV transmission: the genetic bottleneck. Newspaper Article.
    Noble S
    IAVI Rep; 2008; 12(6):4-8. PubMed ID: 20218017
    [No Abstract]   [Full Text] [Related]  

  • 2. New vaccines may keep HIV in check.
    Heltzer NE
    AIDS Read; 2001 Oct; 11(10):486, 504. PubMed ID: 11708080
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV/AIDS: allied responses.
    Mascola JR
    Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
    [No Abstract]   [Full Text] [Related]  

  • 4. IgG surfaces as an important component in mucosal protection.
    Robert-Guroff M
    Nat Med; 2000 Feb; 6(2):129-30. PubMed ID: 10655090
    [No Abstract]   [Full Text] [Related]  

  • 5. DNA vaccines for immunodeficiency viruses.
    Robinson HL
    AIDS; 1997; 11 Suppl A():S109-19. PubMed ID: 9451974
    [No Abstract]   [Full Text] [Related]  

  • 6. Attenuated retrovirus vaccines and AIDS.
    Marx PA
    Science; 1995 Nov; 270(5239):1219-20; author reply 1220-2. PubMed ID: 7502054
    [No Abstract]   [Full Text] [Related]  

  • 7. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV. Escape artist par excellence.
    Cohen J
    Science; 2003 Mar; 299(5612):1505-8. PubMed ID: 12624245
    [No Abstract]   [Full Text] [Related]  

  • 9. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 10. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
    Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ
    Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV/AIDS in China. Vaccine development with a distinctly Chinese flavor.
    Cohen J
    Science; 2004 Jun; 304(5676):1437. PubMed ID: 15178780
    [No Abstract]   [Full Text] [Related]  

  • 13. Feasibility and cohort development for HIV vaccine trials in Haiti.
    Deschamps MM; Johnson WD; Pape JW
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S231-3. PubMed ID: 7865308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV/AIDS research. Potent HIV antibodies spark vaccine hopes.
    Cohen J
    Science; 2009 Sep; 325(5945):1195. PubMed ID: 19729632
    [No Abstract]   [Full Text] [Related]  

  • 15. Prime-boost immunization strategies against HIV.
    Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune control of HIV: the obstacles of HLA and viral diversity.
    Walker BD; Korber BT
    Nat Immunol; 2001 Jun; 2(6):473-5. PubMed ID: 11376327
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrovirus meeting. Back-to-basics push as HIV prevention struggles.
    Cohen J
    Science; 2008 Feb; 319(5865):888. PubMed ID: 18276859
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic vaccination: where are we now?
    Rosenberg ES
    AIDS Clin Care; 2003 Jan; 15(1):1-3. PubMed ID: 12685420
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
    Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
    Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
    [No Abstract]   [Full Text] [Related]  

  • 20. [Perspectives for the development of preventive vaccines against HIV/AIDS].
    Esparza J
    Medicina (B Aires); 1998; 58 Suppl 1():57-63. PubMed ID: 9674249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.